Therapeutic agent

Coenzyme Q10 (CoQ10)

Also known as: Coenzyme Q10 (CoQ10)

PreliminaryEvidence level
4Registered trials
5Conditions
3Study references

Evidence Summary

Evidence Level
Preliminary
Mechanism
Anti-inflammatory, Enrollment: Actual, Enrollment: Estimated, Immunomodulatory
Safety
Very safe; mild GI upset rare. May interact with warfarin (monitor INR). Ubiquinol form preferred for absorption.
Dosing
100–300 mg/day (often 200 mg); 8–12+ weeks in fatigue studies.
Mitochondrial support, fatigue data in ME/CFS. 100-300mg ubiquinol. Very safe; consider with statins or low intake. Common in supportive regimens.

Clinical Trials

4 trial(s) registered

NCT IDTitlePhaseStatus
NCT06597682Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEctionNot applicableNot yet recruiting
NCT03186027Coenzyme Q10 Plus NADH Supplementation in Chronic Fatigue Syndrome/Myalgic EncephalomyelitisNot applicableCompleted
NCT05128292Effect of CoQ10 Plus Selenium Supplementation on Clinical Outcomes and Biochemical Markers in ME/CFS (CoSeME Study)Not applicableCompleted
NCT02063126Clinical Trial to Measure the Maximun HR After ReConnect ® Supplementation vs. Placebo in CFS.Phase 2Completed

Key Studies / References